Cover Image
市場調查報告書

西尼羅病毒感染疾病:開發中產品分析

West Nile Virus Infections - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 201011
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
西尼羅病毒感染疾病:開發中產品分析 West Nile Virus Infections - Pipeline Review, H2 2017
出版日期: 2017年09月19日 內容資訊: 英文 66 Pages
簡介

西尼羅病毒感染疾病,是由蚊子傳播的病毒所引起。西尼羅病毒,又稱黃病毒,是病毒的一種。

本報告提供西尼羅病毒感染疾病的治療藥的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

西尼羅病毒感染疾病概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

西尼羅病毒感染疾病:企業開發中的治療藥

西尼羅病毒感染疾病:大學/機關研究中的治療藥

西尼羅病毒感染疾病:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

西尼羅病毒感染疾病:企業開發中的產品

西尼羅病毒感染疾病:大學/機關研究中的產品

西尼羅病毒感染疾病的治療藥的開發企業

  • BioDiem Ltd
  • CalAsia Pharmaceuticals, Inc.
  • CEL-SCI Corporation
  • Kineta, Inc.
  • Nanotherapeutics, Inc.

西尼羅病毒感染疾病:治療藥的評估

  • 單劑產品
  • 各標的
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

西尼羅病毒感染疾病:最近的開發平台趨勢

西尼羅病毒感染疾病:暫停中的計劃

西尼羅病毒感染疾病:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9738IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide West Nile Virus Infections - Pipeline Review, H2 2017, provides an overview of the West Nile Virus Infections (Infectious Disease) pipeline landscape.

West Nile infection is caused by a virus transmitted by mosquitoes. The West Nile virus is a type of virus known as a Flavivirus. Symptoms include a fever, headache, body aches, skin rash, and swollen lymph glands. Risk factors for developing a more severe form of West Nile virus include conditions that weaken the immune system, such as HIV, organ transplants, and recent chemotherapy, age and pregnancy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide West Nile Virus Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for West Nile Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The West Nile Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for West Nile Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

West Nile Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of West Nile Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for West Nile Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in West Nile Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates West Nile Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for West Nile Virus Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for West Nile Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding West Nile Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • West Nile Virus Infections - Overview
    • West Nile Virus Infections - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • West Nile Virus Infections - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • West Nile Virus Infections - Companies Involved in Therapeutics Development
    • CEL-SCI Corp
    • Fab'entech SA
    • Hemispherx Biopharma Inc
    • Kineta Inc
    • Nanotherapeutics Inc
    • Plex Pharmaceuticals Inc
    • Theravectys SA
  • West Nile Virus Infections - Drug Profiles
    • AGS-v - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Alferon LDO - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BG-323 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Bispecific Monoclonal Antibody for West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FDX-000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HydroVax-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-n3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1148 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KIN-1400 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rintatolimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NS2B-NS3 Protease for Dengue, West Nile Virus and Zika Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit NS5 for Japanese Encephalitis and Viral Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide for Dengue Virus and West Nile Virus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tatbeclin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • West Nile virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • West Nile Virus Infections - Dormant Projects
  • West Nile Virus Infections - Product Development Milestones
    • Featured News & Press Releases
      • Feb 21, 2017: hVIVO notes the initiation of a Phase I clinical trial with AGS-v, a mosquito-borne disease vaccine candidate
      • Jul 06, 2015: NIH-funded vaccine for West Nile Virus enters human clinical trials
      • May 05, 2014: Alferon N Effective Against MERS Virus In-Vitro
      • Sep 12, 2013: Hemispherx Announces Initial Test Results in Biosecurity/Biodefense Arena
      • Sep 06, 2011: Hemispherx Enters Into Strategic Alliance With Armada Health Care For Alferon N Injection
      • Apr 20, 2010: Kineta Scientist to Present Novel Antiviral Research Findings at International Conference
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for West Nile Virus Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • West Nile Virus Infections - Pipeline by CEL-SCI Corp, H2 2017
  • West Nile Virus Infections - Pipeline by Fab'entech SA, H2 2017
  • West Nile Virus Infections - Pipeline by Hemispherx Biopharma Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Kineta Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Nanotherapeutics Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H2 2017
  • West Nile Virus Infections - Pipeline by Theravectys SA, H2 2017
  • West Nile Virus Infections - Dormant Projects, H2 2017
  • West Nile Virus Infections - Dormant Projects, H2 2017 (Contd..1), H2 2017

List of Figures

  • Number of Products under Development for West Nile Virus Infections, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Top 10 Targets, H2 2017
  • Number of Products by Stage and Top 10 Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Top 10 Molecule Types, H2 2017
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017
Back to Top